Does IMDX pay a dividend and is it safe?

Insight Molecular Diagnostics Inc. (IMDX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / IMDX / dividends

ICCC (59) TKNO (42) NNNN (35) MYGN (47) ⌘ Pro Terminal →

Insight Molecular Diagnostics Inc. (IMDX) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.86 -3.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.84

Insight Molecular Diagnostics Inc. (IMDX) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $96.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IMDX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IMDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $2.86 (-3.38% 1D, market cap $96.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IMDX ranks #927 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IMDX compare to ICCC and TKNO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), IMDX carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of 56.7%, and ROIC of -35.0%. By comparison, ICCC (ImmuCell Corporation) holds a C- grade (59/100 RQD, P/E N/A, ROIC 4.2%, cap $93.2M) and TKNO (Alpha Teknova Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -21.3%, cap $454.1M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IMDX?

▼

Per IMDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001642380), Insight Molecular Diagnostics Inc. generated $4.1M in revenue (+115.6% YoY), -$50.2K in net income, and -$25.4M in free cash flow against $25.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.84 (-0.80%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-14.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMDX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (25/100 Composite)

🔍 WHY IMDX SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (44% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (16% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 56.7% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.99+1.3% Next Q

Q2 (-2Q)

Grade E$3.03+4.3% Next Q

Q3 (-1Q)

Grade E$3.16-9.5% Next Q

Current

Grade E$2.86-10.7% Hist 90D α

Trajectory: E (33) → E (25)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMDX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMDX currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.57) and Max Pain ($3.00) forces dealer call-delta covering toward $8.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IMDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 25%NO 75%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMDX)

✓Walkthrough of IMDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IMDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -45.32%▼ DESCENDING CHANNEL

2026-11-03O $3.18H $3.18L $2.86C $2.86VOL 62.0K

RES: $3.32SUP: $2.29SMA50: $3.57SMA200: $4.70

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMDX Butterfly Map → + Track IMDX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +115.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IMDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IMDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMDX)

Health Care Rank #927 of 1015 ⚔️ ICCC vs IMDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMDX vs. ICCC, TKNO, NNNN, MYGN)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Insight Molecular Diagnostics Inc. (IMDX) ranks #927 by composite RQD confidence (25/100, grade E) and #658 by equity capitalization ($96.9M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. ICCC currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with IMDX at 25/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IMDX ACTIVE Insight Molecular Diagnostics Inc.	E	25/100	—	56.7%	-35.0%	-3.38%	$96.9M	Benchmark Subject
ICCC ImmuCell Corporation	C-	59/100	—	41.4%	4.2%	+2.92%	$93.2M	/iccc-vs-imdx →
TKNO Alpha Teknova Inc.	D-	42/100	—	33.2%	-21.3%	-4.75%	$454.1M	/tkno-vs-imdx →
NNNN Anbio Biotechnology (Class A)	D-	35/100	83.6x	87.2%	17.0%	+4.46%	$483.5M	/nnnn-vs-imdx →
MYGN Myriad Genetics Inc.	D	47/100	—	69.9%	-35.0%	-7.87%	$607.4M	/mygn-vs-imdx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001642380 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Insight Molecular Diagnostics Inc. (IMDX) reported GAAP revenue of $4.1M (+115.6% vs. FY2024 revenue of $1.9M , and +169.8% cumulative change since FY2023) , GAAP net income of -$50.2K, operating cash flow of -$22.2M, and free cash flow of -$25.4M (-19.6% YoY). On the balance sheet, IMDX closed FY2025 with $25.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.1M	-$50.2K	-$22.2M	-$25.4M	$25.8M	—
FY2024 (FY)	2024-12-31	$1.9M	-$60.7K	-$20.7M	-$21.2M	$35.1M	—
FY2023 (FY)	2023-12-31	$1.5M	-$27.8K	-$23.3M	-$23.3M	—	—

3. IMDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IMDX compare to ICCC and TKNO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IMDX?

Where is IMDX trading relative to its 50-day, 200-day, and 52-week technical levels?

IMDX last traded at $2.86 (-3.38% on volume of 127,791 shares), positioning the stock -19.89% below its 50-day simple moving average ($3.57) and -39.15% below its 200-day simple moving average ($4.70). Across its 52-week range of $2.42 to $8.51, IMDX sits at the 7.2% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.50 to $3.22).

Direct Sub-Reports: IMDX RQD Cockpit IMDX 12M Forecast IMDX Earnings & Move IMDX Dividends & DRIP IMDX Insiders & 13F IMDX Whale Options IMDX Profit Sankey IMDX News & Why

ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ SEC XBRL & RQD VERIFIED

IMDX — Insight Molecular Diagnostics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Insight Molecular Diagnostics Inc. (IMDX) earns a live Roarable RQD composite score of 25/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.86 (-3.38% 1D, market capitalization $96.9M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 56.7%, operating margin of -60.0%, and free cash flow yield of -24.38%.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (4/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Insight Molecular Diagnostics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. The profile describes the company as a Health Care issuer with a market capitalization of $0.1B. Per the RSS news items, the company is preparing a planned GraftAssureDx launch and has referenced transplant testing. — for specific customer segments or detailed revenue model mechanics beyond these references.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Insight Molecular Diagnostics Inc. (IMDX) reported $4.1M in annual revenue (up from $1.9M in FY2024, +115.6% YoY) and -$50.2K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.5M revenue, -$27.8K net income) through FY2025, IMDX scaled operating cash flow to -$22.2M and free cash flow to -$25.4M, backed by $25.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 25/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -24.38% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.42 – $8.51 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph reports no upstream or downstream links and no proprietary signals, so no supply-chain dependencies, sector correlations, or second-order bottlenecks can be mapped from the provided sources.

Key Question #1: Can IMDX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $4.1M and free cash flow of -$25.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is IMDX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IMDX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Insight Molecular Diagnostics Inc. (IMDX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IMDX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch

Yahoo Finance report covering Insight Molecular Diagnostics Inc. (IMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

IMDX Q3'26 Earnings: revenue estimate is 235.12K USD

TradingView report covering Insight Molecular Diagnostics Inc. (IMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings

Yahoo Finance report covering Insight Molecular Diagnostics Inc. (IMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE scanx.trade • 1d ago

Medicare policy boosts iMDx transplant testing frequency

scanx.trade report covering Insight Molecular Diagnostics Inc. (IMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

Insight Molecular Diagnostics (IMDX) Climbs 2.74% to $3.37, Pressing Against Near-Term Resistance - Merger Arbitrage

https://www.dars.gov.et/ report covering Insight Molecular Diagnostics Inc. (IMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Insight Molecular Diagnostics Inc. (IMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingKey • 1d ago

Top U.S. Stock Gainers: Biggest Price Increases

TradingKey report covering Insight Molecular Diagnostics Inc. (IMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

IMDX Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Edge Lower - Final Results

https://www.dars.gov.et/ report covering Insight Molecular Diagnostics Inc. (IMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IMDX Bull vs. Bear Conversation Board — What's Your Call at $2.86?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMDX 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $3.58 (+20.9%)

📌 Pinned Debate

Revenue grew from $1.5M in FY 2023 to $4.1M in FY 2025 while cash rose from $8.6M to $11.6M, and the Forensic Balance Sheet pillar scor

Revenue grew from $1.5M in FY 2023 to $4.1M in FY 2025 while cash rose from $8.6M to $11.6M, and the Forensic Balance Sheet pillar scores 11/20 with an Altman Z of 2.5.. When you look under the hood at IMDX, Fundamental Cash Engine is 4/20 with 56.7% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $8.51. My 12M target is $3.58.

CapAlloc_Nerd 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: In Vitro & In Vivo Diagnostic Substances. If gross margin (56.7%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $2.28 (-23.0%)

Spot @ $2.96

Operating income of -$51.1M and free cash flow of -$25.4M in FY 2025, with ROIC at -35% and FCF yield at -24.38%, leave the Fundamental

Fading this rally in IMDX at $2.96. Operating income of -$51.1M and free cash flow of -$25.4M in FY 2025, with ROIC at -35% and FCF yield at -24.38%, leave the Fundamental Cash Engine pillar at only 4/20.. With a beta of 1.0 and the stock sitting at $2.96 (52-wk range $2.42–$8.51), the easy multiple expansion is already priced in.